Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.55 |
| ▸ | NOS1 | P29475 | 3/20 | 0.55 |
| ▸ | NOS2 | P35228 | 3/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155234 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL4595466 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL29750308 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL22190028 | 0.88 | NOS3 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL7418862 | 0.88 | NOS3 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL7375715 | 0.86 | ALDH1A1 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL29785614 | 0.86 | ALDH1A1 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL7885274 | 0.86 | ALDH1A1 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL30013379 | 0.86 | ALDH1A1 (0.50) | NOS3NOS1NOS2ALPIPKM | |
| SCHEMBL13957680 | 0.86 | IDO1 (0.53) | NOS3NOS1NOS2ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| CN-1119340-C | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2003-08-27 | — | — | CN | claimed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | Fraunhofer-Gesellschaft Zur Forderung Der Angewanditen Forschung (DE) | 2026-01-27 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4651906-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | Ambrx, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20050256056-A1 | Peptide inhibitors of HIV | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | US | disclosed |
| CN-1119340-C | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| CN-1230175-A | Cytostatic hydroximic acid derivatives | BRITISH BIOTECH PHARM (GB) | 1999-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | NOS3 3751/4885NOS1 3043/4885NOS2 3668/4885 |
| US-20050256056-A1 | Peptide inhibitors of HIV | VIP, NGLY1, PEPD | NOS3 2889/4885NOS1 2925/4885NOS2 3557/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | NOS3 3324/4885NOS1 2043/4885NOS2 3210/4885 |
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | VIP, LNPEP, SARS1 | NOS3 1903/4885NOS1 3094/4885NOS2 3131/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | NOS3 2114/4885NOS1 3356/4885NOS2 3488/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | NOS3 3771/4885NOS1 4059/4885NOS2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.